Novacyt S.A.
LSE: NCYT.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Lyn Dafydd Rees
- Employees
- 234
- Headquarters
- Le Vésinet, France
- IPO year
- 2017
- Market cap
- £33.8M
- Website
- https://www.novacyt.com
Loading NCYT…
Loading profile data…Frequently asked questions about NCYT
What does Novacyt S.A. (NCYT.L) do?
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-...
Where does NCYT.L trade?
Novacyt S.A. (NCYT.L) trades on the London Stock Exchange.
What sector is NCYT.L in?
Novacyt S.A. (NCYT.L) operates in the Healthcare sector, specifically in the Medical - Devices industry.
Who is the CEO of Novacyt S.A.?
Lyn Dafydd Rees is the chief executive officer of Novacyt S.A. (NCYT.L).
Where is Novacyt S.A. headquartered?
Novacyt S.A. is headquartered in France.
Does NCYT.L pay a dividend?
Novacyt S.A. (NCYT.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NCYT.L go public?
Novacyt S.A. (NCYT.L) completed its initial public offering in 2017.